Login to Your Account



Washington Roundup

Generic Industry Accuses Biotech of 'Cutting a Deal'

By Donna Young


Tuesday, February 19, 2008
WASHINGTON - The biotech and pharmaceutical makers' support for getting a follow-on biologics bill passed this year is an attempt to "cut a deal" with Congress to secure at least 12 years of data exclusivity, said Kathleen Jaeger, CEO of the Generic Pharmaceutical Association (GPhA). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription